Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04104581
Other study ID # HS64 Daily Grain
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 4, 2019
Est. completion date March 16, 2020

Study information

Verified date March 2020
Source USDA Beltsville Human Nutrition Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to identify markers of daily whole grain oat and whole grain wheat intake in humans.


Description:

The aim of this study is to identify compounds that are found in blood and urine and are derived from repeated daily consumption of whole grain oat or whole grain wheat intake so that epidemiological studies can be conducted to provide more accurate associations between whole grain intake and health.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date March 16, 2020
Est. primary completion date March 16, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria:

- Aged 21 - 75 years

- non smokers

Exclusion Criteria:

- Body weight less than 110 lbs.

- Have a body mass index below 19 or above 38 kg/m2

- Known (self-reported) allergy or adverse reaction to study foods

- Women who have given birth during the previous 12 months or who are pregnant/lactating or who plan to become pregnant during the study

- History of bariatric surgery or nutrient malabsorption disease (such as celiac disease), Crohn's disease, diabetes, or metabolic disorders that may interfere with the study

- History of certain cancer diagnosis or treatment in the last 3 years

- Smoking or use of tobacco products in the past 6 months

- Suspected or known strictures, fistulas or physiological/mechanical GI obstruction

- Use of certain medications or supplements (prescription or over-the-counter) that may interfere with the study objectives, including blood thinning medications

- Unable or unwilling to give informed consent or communicate with study staff

- Self-report of alcohol or substance abuse within the past 12 months and/or current treatment for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)

- Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control Refined Grain Diet
Subjects will be fed the average American diet except it will be free of whole grains
Low Whole Grain Oat Diet
Subjects will be fed the average American diet with addition of a low level of whole grain oats
High Whole Grain Oat Diet
Subjects will be fed the average American diet with addition of a high level of whole grain oats
Low Whole Grain Wheat Diet
Subjects will be fed the average American diet with addition of a low level of whole grain wheat
High Whole Grain Wheat Diet
Subjects will be fed the average American diet with addition of a high level of whole grain wheat

Locations

Country Name City State
United States USDA-ARS Beltsville Human Nutrition Research Center Beltsville Maryland

Sponsors (2)

Lead Sponsor Collaborator
USDA Beltsville Human Nutrition Research Center National Institute of Food and Agriculture

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1 of Period 1 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1 of Period 2 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1 of Period 3 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1 of Period 4 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1 of Period 5 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 8 of Period 1 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 8 of Period 2 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 8 of Period 3 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 8 of Period 4 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 8 of Period 5 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 15 of Period 1 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 15 of Period 2 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 15 of Period 3 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 15 of Period 4 (period = 15 days)
Primary Identification of unknown blood biomarkers of grain intake Metabolomic analysis of blood samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 15 of Period 5 (period = 15 days)
Secondary Identification of unknown urinary biomarkers of grain intake Metabolomic analysis of urine samples will be conducted; the selected intensity of biochemicals identified from liquid and gas chromatography with mass ranging from 50 to 800 molecular weight will be determined Day 1, 8, and 15 of each of the 5 fifteen day diet periods
Secondary Characterization of fecal microbiota Fecal samples will be analyzed for microbiota Day 1, 8, and 15 of each of the 5 fifteen day diet periods
Secondary Blood Glucose Fasting blood glucose will be measured in mg/dL Day 1 and 15 of each of the 5 fifteen day diet periods
Secondary Blood Insulin Fasting blood insulin will be measured in uIU/mL Day 1 and 15 of each of the 5 fifteen day diet periods
Secondary Blood Triglycerides Fasting blood triglycerides will be measured in mg/dL Day 1 and 15 of each of the 5 fifteen day diet periods
Secondary Blood Non-Esterified Fatty Acids Fasting blood non esterified fatty acids will be measured in mEQ/L Day 1 and 15 of each of the 5 fifteen day diet periods
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1